research Using 5 alpha reductase inhibitors safely: What primary care physicians need to know
5 alpha reductase inhibitors can cause sexual, cognitive, and muscle side effects, and may slightly increase aggressive cancer risk.
Search
for
Sort by
Research
150-180 / 1000+ results 
research Patient Profile and Treatment Characteristics of Adults and Adolescents Prescribed Ritlecitinib for Alopecia Areata in the USA
Ritlecitinib provides new treatment options for diverse alopecia areata patients.
research Ruxolitinib: A novel molecule in the management of dermatological disorders
Ruxolitinib cream effectively treats skin conditions like atopic dermatitis and vitiligo with minimal side effects.
research Comprehensive Safety Exposure‐Response Analysis to Support Ritlecitinib Dose Selection
A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
research Increase in formalin-induced tonic pain by 5alpha-reductase and aromatase inhibition in female rats
Inhibiting certain enzymes made female rats more sensitive to low-level pain.
research Reporting on Adverse Clinical Events
Monitoring for adverse effects in clinical treatments is crucial.
research Association of breast cancer in men with exposure to 5-α reductase inhibitors: A RADAR report.
Taking 5-alpha reductase inhibitors might be linked to breast cancer in men.
research Patient Considerations when Using Ritlecitinib for Alopecia Areata in Adolescents: Guidance for the Clinicians
Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.
research An exploratory analysis of 5‐alpha reductase inhibitors and risk of opioid use disorder among male Medicare beneficiaries receiving prescription opioid medications
Using 5-alpha reductase inhibitors may lower the risk of opioid addiction in men taking opioids.
research Ozenoxacin suppresses sebum production by inhibiting mTORC1 activation in differentiated hamster sebocytes
Ozenoxacin reduces sebum production, helping manage acne.
research Natural Product-InspiredBis(trifluoromethyl) PhenylHydroxycinnamate Derivatives as Promising Nonsteroidal Inhibitorsof Human Steroid 5α-Reductase Type-1: Synthesis, InVitro, and In Silico Studies
Certain hydroxycinnamate derivatives may effectively inhibit enzymes linked to hair loss with low toxicity.
research Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof-of-concept studies
Fulvestrant solution doesn't help hair loss in men and postmenopausal women.
research LB891 Analysis of breast health outcomes in women on oral 5-alpha reductase inhibitors: A single-center retrospective cohort study
5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.
research LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1.
LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.
research Inhibition of 5α-reductase in the rat prostate by Cimicifuga racemosa
Cimicifuga racemosa extract may help prevent and treat prostate issues by inhibiting 5α-reductase.
research Synthesis and 5α-Reductase Inhibitory Activity of C21 Steroids Having 1,4-diene or 4,6-diene 20-ones and 4-Azasteroid 20-Oximes
Three specific 4-azasteroid-2-oximes showed strong enzyme inhibition, but less than finasteride.
research Finasteride/flibanserin
research Reversal of male-pattern baldness, hypertrichosis, and accelerated hair and nail growth in patients receiving benoxaprofen.
research Off‐Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives
Topical ruxolitinib may help some skin conditions but needs more research for alopecia areata.
research Anti-nociceptive and anti-inflammatory properties of 5alpha-reductase inhibitor finasteride in experimental animals
Finasteride helps reduce pain and inflammation in animals.
research Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
research Association Between Retinoid X Receptor Gene Variants and Dyslipidemia Risk in an Iranian Population
The rs1128977 gene variant may affect cholesterol and body measurements.
research Protective Effect of “ Ark‐e‐Kasni ,” a Unani Formulation, in Letrozole and High‐Fat Diet–Induced Polycystic Ovarian Syndrome in Rats
Ark-e-Kasni improves PCOS symptoms and may be a potential treatment.
research Off-label prescriptions: patient safety first
Off-label drug use can be risky and requires careful consideration to ensure patient safety.
research Steroid 5α-reductase inhibition by polymethoxyflavones
Certain natural compounds can block an enzyme linked to prostate enlargement and hair loss, showing potential for new treatments.
research Real-world assessment of ritlecitinib in patients with severe alopecia areata: a 24-week multicentre retrospective study
Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
research Faculty Opinions recommendation of Association between 5-alpha reductase inhibition and risk of hip fracture.
5-alpha reductase inhibitors do not increase hip fracture risk.
research Finasteride/spironolactone
research Alopecia associated with strontium ranelate use in a 62-year-old woman
A woman experienced hair loss after taking strontium ranelate for osteoporosis.
research 17-Oximino-5-androsten-3β-yl esters: synthesis, antiproliferative activity, acute toxicity, and effect on serum androgen level
Some synthesized compounds were more effective than Finasteride in reducing prostate cancer cell growth and androgen levels.